Monoclonal antibodies: versatile platforms for cancer immunotherapy

被引：935

作者：

Weiner, Louis M. ^{[1
]}

Surana, Rishi ^{[1
]}

Wang, Shangzi ^{[1
]}

机构：

[1] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA

来源：

NATURE REVIEWS IMMUNOLOGY | 2010年 / 10卷 / 05期

基金：

美国国家卫生研究院;

关键词：

GROWTH-FACTOR RECEPTOR; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; TYROSINE KINASE INHIBITOR; NEONATAL FC-RECEPTOR; PHASE-I; THERAPEUTIC ACTIVITY; ANTITUMOR-ACTIVITY; 1ST-LINE TREATMENT;

D O I：

10.1038/nri2744

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antibodies are important therapeutic agents for cancer. Recently, it has become clear that antibodies possess several clinically relevant mechanisms of action. Many clinically useful antibodies can manipulate tumour-related signalling. In addition, antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses. These immunomodulatory properties can form the basis for new cancer treatment strategies.

引用

页码：317 / 327

页数：11

共 119 条

[1] Monoclonal antibody therapy of cancer [J].

Adams, GP ;

Weiner, LM .

NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157

[2] Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma [J].

Advani, Ranjana ;

Forero-Torres, Andres ;

Furman, Richard R. ;

Rosenblatt, Joseph D. ;

Younes, Anas ;

Ren, Hong ;

Harrop, Kate ;

Whiting, Nancy ;

Drachman, Jonathan G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4371-4377

[3]

ALBERT ML, 1998, IRESTRICTED CTLS NAT, V392, P86

[4] Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon [J].

Alpaugh, RK ;

von Mehren, M ;

Palazzo, I ;

Atkins, MB ;

Sparano, JA ;

Schuchter, L ;

Weiner, LM ;

Dutcher, JP .

MEDICAL ONCOLOGY, 1998, 15 (03) :191-198

[5] Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells [J].

Berard, F ;

Blanco, P ;

Davoust, J ;

Neidhart-Berard, EM ;

Nouri-Shirazi, M ;

Taquet, N ;

Rimoldi, D ;

Cerottini, JC ;

Banchereau, J ;

Palucka, AK .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (11) :1535-1543

[6] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].

Berger, Raanan ;

Rotem-Yehudar, Rinat ;

Slama, Gideon ;

Landes, Shimon ;

Kneller, Abraham ;

Leiba, Merav ;

Koren-Michowitz, Maya ;

Shimoni, Avichai ;

Nagler, Arnon .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051

[7] Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan [J].

Bibeau, Frederic ;

Lopez-Crapez, Evelyne ;

Di Fiore, Frederic ;

Thezenas, Simon ;

Ychou, Marc ;

Blanchard, France ;

Lamy, Aude ;

Penault-Llorca, Frederique ;

Frebourg, Thierry ;

Michel, Pierre ;

Sabourin, Jean-Christophe ;

Boissiere-Michot, Florence .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1122-1129

[8] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope ;

Sledge, George ;

Koehler, Maria ;

Ellis, Catherine ;

Casey, Michelle ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130

[9] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[10] MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors [J].

Brischwein, K ;

Schlereth, B ;

Guller, B ;

Steiger, C ;

Wolf, A ;

Lutterbuese, R ;

Offner, S ;

Locher, M ;

Urbig, T ;

Raum, T ;

Kleindienst, P ;

Wimberger, P ;

Kimmig, R ;

Fichtner, I ;

Kufer, P ;

Hofmeister, R ;

da Silva, AJ ;

Baeuerle, PA .

MOLECULAR IMMUNOLOGY, 2006, 43 (08) :1129-1143

← 1 2 3 4 5 6 7 8 9 10 →